Fundamentals Hub
ACXP Acurx Pharmaceuticals, Inc.
ACXP financial statements, revenue, balance sheet, cash flow, and SEC filings
Showing 3 of 6 annual and 0 of 24 quarterly periods.
Full history available with a free account or via API.
▼ Company Profile
Filer Category
<br>Emerging growth company
Entity Type
Operating
Public Float
$13.70M (Jun 2025)
Industry (SIC)
2834 Pharmaceutical Preparations
Incorporated
DE
Fiscal Year End
December (1231)
Phone
917-533-1469
EIN
000000000
Headquarters
STATEN ISLAND, NY, 10305
Public Float History
Market value of shares held by public investors, reported in annual DEI filings.
Former Names:
Acurx Pharmaceuticals, LLC (2018–2021)
▼ Key Metrics (TTM)
As of Jun 30, 2026Financials
Revenue
-
Net Income
$-7.51M
Total Assets
$10.98M
Total Equity
$8.15M
Total Debt
-
Free Cash Flow
-
Ratios
Return on Equity
-92.1%
Return on Assets
-68.3%
Sources and calculation details
Reported values are preserved. Derived values use the listed inputs; unavailable inputs remain blank.
Field-level sources for this historical record are unavailable until it is rebuilt from SEC facts.
Annual (FY)
Quarterly 🔒
Chart 🔒
| Metric | FY2025 📄 | FY2024 📄 | FY2023 📄 |
|---|---|---|---|
| Income Statement | |||
| REVENUE | |||
| OPERATING EXPENSES | |||
| R&D Expense | $1.83M | $5.40M | $6.04M |
| SG&A Expense | $6.26M | $8.72M | $8.53M |
| Operating Income | $-8.09M | $-14.12M | - |
| NON-OPERATING INCOME / EXPENSE | |||
| Interest Income | $125.45K | $20.12K | - |
| Net Income | $-7.97M | $-14.10M | $-14.58M |
| PER SHARE & SUPPLEMENTAL | |||
| Diluted EPS | $-5.32 | $-17.45 | $-1.15 |
| Diluted Shares | 1.50M | 808.17K | 12.67M |
| Balance Sheet | |||
| ASSETS | |||
| Cash & Equivalents | $7.56M | $3.71M | $7.47M |
| Other Current Assets | $85.02K | $100.12K | $105.78K |
| Total Assets | $7.69M | $3.86M | $7.71M |
| LIABILITIES | |||
| Accounts Payable | $2.42M | $3.24M | $3.04M |
| Current Liabilities | $2.42M | $3.24M | $3.04M |
| Noncurrent Liabilities | $0 | $0 | $0 |
| Total Liabilities | $2.42M | $3.24M | $3.04M |
| EQUITY | |||
| Common Stock | $2.35K | $852 | $14.47K |
| Additional Paid-in Capital | $80.55M | $67.94M | $57.87M |
| Retained Earnings | $-75.29M | $-67.32M | $-53.22M |
| Total Equity | $5.27M | $615.12K | $4.67M |
| Total Liabilities & Equity | $7.69M | $3.86M | $7.71M |
| SUPPLEMENTAL | |||
| Shares Outstanding | 2.35M | 851.53K | 14.47M |
| Check: A − (L + E + Temp. Equity) | - | - | - |
| Cash Flow Statement | |||
| Cash from Operations | $-6.79M | $-10.38M | $-9.80M |
| Capital Expenditures | - | - | - |
| Cash from Investing | $0 | $0 | $0 |
| Cash from Financing | $10.64M | $6.62M | $8.16M |
| Free Cash Flow | - | - | - |
| Beginning Cash (CFS) | $3.71M | $7.47M | $9.11M |
| Net Change in Cash | $3.85M | $-3.77M | $-1.64M |
| Effect of FX on Cash | - | - | - |
| Calculated Ending Cash | $7.56M | $3.71M | $7.47M |
| Cash per BS | $7.56M | $3.71M | $7.47M |
| Cash scope difference (CFS − BS) | - | - | - |
| Cash per CFS | $7.56M | $3.71M | $7.47M |
Create a free account to see full history, quarterly data, charts, CSV downloads, and API access.
Create Free Account Log In🔒
Quarterly data and charts require a free account
Get access to 8 quarters of data, interactive charts, CSV downloads, and API access.
▼ Frequently Asked Questions
Is Acurx Pharmaceuticals, Inc. profitable?
No. Acurx Pharmaceuticals, Inc. reported $-7.51M in net income for trailing twelve months. Profitability data is based on the company's most recent annual report filed with the SEC.